Iris Unito Prodmetadata only
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
durvalumab, epidermal growth factor receptor, etoposide, neuroendocrine transformation, non-small cell lung cancer, osimertinib, platinum-based chemotherapy
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 326525
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.